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A B S T R A C T
The best option for the treatment of a failing heart is heart transplantation. The transplantation program at the Uni-
versity Hospital Center Rebro Zagreb started in 1988. To the best of our knowledge this is the first retrospective study on
cardiac transplantation in Croatia looking into survival following heart transplantation. Between 1988 and 2006, we
performed 81 heart transplantations at the University Hospital Center Rebro Zagreb. Our study focused on the last ten
years after establishment of the Department of cardiac surgery as a separate institution. There were thirteen different
hospitals throughout Croatia, which contributed to the donor network. Average age of the heart recipient was 48±11.8
years (range 14–72), and average age of the heart donor was 34±10.7 years (range 14–56). There were more women
among the heart donors (34%) then among the heart recipients (18%). During the first ten years, from 1988–1998, the av-
erage number of cardiac transplantations was 3 per year. In the period from 1998–2006, average number of cardiac
transplantations increased to 6 per year. The average thirty-day mortality for the last nine years was 27%. It declined
from 30% and 40% in 1998 and 1999, respectively down to 0% in the last two years. Average age of the patients who died
was 50±6.5 years (range 44–62) and did not significantly differ from those who survived. The donor network has grown
up to fourteen different hospitals throughout Croatia. The limiting factor in cardiac transplant surgery is the number of
available donors. Therefore in attempt to form a good transplant program it is crucial to form an efficient donor network.
The number of performed cardiac transplantations is expected to rise until it reaches the number of available donors.
With advances in operative technique and postoperative management – immunosuppressive therapy we have observed a
remarkable drop in the early operative mortality in the studied period.
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Introduction
The treatment of heart failure utilizes a substantial
proportion of funds in health care systems of developed
countries. According to Cowie, 1999, a crude prevalence
is 3 to 20 per 1000 in the general population1 with con-
stantly increasing incidence. Heart failure has a substan-
tial risk of death, which is around 66% for men and 50%
for women in the period of five years2,3. Heart failure is
one of the most common reasons for hospital admissions
in the elderly. Readmission is quite common even within
6 months. EuroHeart failure survey showed that sus-
pected or confirmed heart failure caused 20% of read-
missions4.
The heart transplant surgery begun with French sur-
geon Alexis Carrel, who performed the first heterotopic
canine heart transplant at the very beginning of the 20th
century5,6. The era of human heart transplantation start-
ed with Christian Barnard who performed the first suc-
cessful human to human heart transplantation in South
Africa in 19677. Shumway and his colleagues at the Stan-
ford University revitalized cardiac transplantation in the
late 1970s. Josip Sokolic performed the first successful
human to human heart transplantation in Croatia in
1988 at the University Hospital Center Rebro Zagreb. In-
troduction of transvenous endomyocardial biopsy as effi-
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cient means of monitoring allograft rejection and recent
progress in immunosuppresion and infection control has
transformed cardiac transplantation and marked the be-
ginning of the modern era of successful cardiac trans-
plantation. Cardiac transplantation is widely accepted as
a therapeutic procedure of choice for patients with end-
-stage heart failure. Ventricular assisting devices are now
additional efficient means of treatment of heart failure
used as a destination therapy or as a bridge to transplan-
tation.
Patients with ischemic heart disease or idiopathic di-
lated cardiomyopathy that is not amenable to medical or
surgical therapy comprise the group of candidates for
heart transplantation. Those are patients with left ven-
tricular ejection fraction lower than 20%, with high pul-
monary capillary wedge pressure classified in New York
Heart Association class III or IV with8–10. Oxygen con-
sumptionMVO2 should be equal or less than 14 L/min/kg.
Expected 1-year survival in the group of patients that
are considered to meet the above mentioned criteria for
heart transplantation is less than 50% without trans-
plantation11–17.
Heart transplantation has its contraindications. Ma-
jor concern in the early postoperative period is the func-
tion of the right ventricle. There are several reasons for
such concern. First, depending on the method of delivery,
cardioplegia reaches right heart chambers less efficiently
than the left ones. This is often times a cause of myocar-
dial stunning and reperfusion injury. On top of that,
given usual long duration of heart failure before patients
meet criteria for transplantation, recipients often times
have some degree of pulmonary vascular hypertension
and increased pulmonary vascular resistance, which both
put the right heart under a higher strain and can both
precipitate right heart failure. Fixed pulmonary vascular
resistance greater than six Wood units is an absolute con-
traindication for heart transplantation and those patients
should undergo heart-lung transplantation if possible18–25.
General contraindications for cardiac transplantation are
active infection, renal or hepatic dysfunction, chronic
lung disease, severe peripheral atherosclerotic vascular
disease, severe systemic connective tissue disorder (SLE),
sarcoidosis and malignancy to mention some of the most
common ones. End-organ damage such as nephropathy
or retinopathy in diabetes is contraindication for heart
transplantation26,27. The upper age limit, as a cut off for
heart transplant, is currently defined as age>70 years.
Older patients tend to have more advanced systemic dis-
eases and somewhat higher rate of complications after
surgery. However the quality of life after transplantation
and survival is comparable to the younger ones.
Patients and Methods
We performed first retrospective study on cardiac
transplantation in Croatia since it first begun in 1988.
There were total of 81 human-to-human cardiac trans-
plantations performed at the University Hospital Center
Rebro Zagreb, but our database covered only the period
of last 9 years. During that period of time we performed
fifty-one heart transplantations. Technique that we used
was orthotopic heart transplantation with no heterotopic
transplantations. Average age of the heart recipient was
48±11.8 years (range 14–72), and average age of the
heart donor was 34±10.7 years (range 14–56). There
were more women among the heart donors (34%) com-
pared to the heart recipients group (18%). There were no
heart re-transplantations and none of heart recipients
has undergone major cardiac surgery such as valve re-
placement or aortocoronary bypass after successful car-
diac transplantation.
Immunosuppressive protocol at our institution in-
cluded combination of corticosteroids, cyclosporine, and
azathioprine. Azathioprine was later on excluded from
the protocol and replaced with mycophenolate mofetil
due to its potential toxicity. We titrated cyclosporine to
achieve a serum level between 100 and 300 ng/mL. Cor-
ticosteroids were first line therapy for acute rejection.
Recently we included polyclonal anti-T-cell preparations
(ATG) in the early postoperative period. In our current
immunosuppressive protocol ATG is replaced with cyclo-
sporine after 3 days. Corticosteroid regimen started with
solumedrol at 1.5 mg/kg four times per day. By the post-
operative day seven solumedrol was replaced with pred-
nisone starting at 50mg twice a day and further titrated
depending on the level of rejection. The bicaval heart
transplantation technique as we perform it is shown in
Figure 1a–d.
Results
We observed an average number of 3 heart transplan-
tations per year till 1998. After the Department of the
cardiac surgery was formed as a separate institution in
1998 average number of cardiac operations increased to
6 per year (Figure 2).
There were 51 cardiac transplantations in the last
nine years compared to 30 during the first ten years.
First nineteen explantations were all performed at
the University Hospital Center Rebro Zagreb. Ever since
the first donor heart came from Rijeka in the year 1994,
donor network has expanded to a total of fourteen Hospi-
tals throughout Croatia (Table 1).
Average thirty-day mortality for the last nine years
was 27%. It dropped from 30 and 40% in 1998 and 1999,
respectively down to 10% in the last four years (table 2).
Average age of the patients who died was 50±6.5 years
(44–62) and did not significantly differ from patients who
survived (p=0.066 according to student T test).
Discussion
Long-term survival of the transplanted heart recipi-
ent is limited firstly by allograft rejection and side effects
of immunosuppression. It was the advent of cyclosporine
that significantly changed survival, marking the begin-
ning of modern era of cardiac transplantation. Imu-
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nosuppression is crucial to the success of cardiac trans-
plantation, especially in the early induction phase. Most
centers use tipple immunosuppressive regimen with var-
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Fig. 1. Bicaval heart transplantation technique: a) first, left atrial anastomosis is created, b) followed by inferior vena cava and aorta
(as shown on the figure). c) Transplantation is completed once pulmonary artery and finally d) superior vena cava have been created.
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Fig. 2. Number of cardiac transplantations per year.
TABLE 1
THE DONOR NETWORK – CONTRIBUTION OF DIFFERENT
HOSPITALS TO THE HEART TRANSPLANT PROGRAM
City Number of donors %
Zagreb 42 52.5
Split 6 7.5
Varazdin 6 7.5
Rijeka 5 6.3
Osijek 4 4.4
Dubrovnik 3 3.7
Pula 3 3.7
SI. Brod 2 2.5
Zadar 1 1.3
Sibenik 1 1.3
Karlovac 1 1.3
Cakovec 1 1.3
Koprivnica 1 1.3
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ious dosages. In patients that develop complications as-
sociated with immunosuppressive agents some nonphar-
macological immunosuppression may play a significant
role. Radiation to lymphatic tissues provides several we-
eks of nonspecific immunosuppression. Peripheral mono-
nuclear antibodies obtained via leukophoresis have a
suppressor effect on T lymphocytes and they may reverse
acute rejection. Plasma exchange may permit removal of
circulating antibodies.
Operative (i.e., 30-day) mortality for cardiac trans-
plantation ranges from 5 to 10%28. We reported a higher
30-day mortality (average 27%), but it has been signifi-
cantly reduced in the last four years to 10% and it is ex-
pected to further decline with larger series of patients.
Average age of the heart recipient (48 years) in our group
is still well bellow 65 years of age which is generally con-
sidered upper limit for cardiac transplantation eligibility.
We expect that the average age of our patients rises.
Some of our patients will need retransplantation and
some will undergo valve replacement or aortocoronary
bypass procedures given the natural course of coronary
artery disease and valve degeneration.
The increased success of the cardiac transplantation
resulted in more operations per year with the same num-
ber of available organs. Number of cardiac transplanta-
tions in Croatia is still below number of available donors.
In most western countries number of donors is the limit-
ing factor for cardiac transplantations. Xenograft trans-
plantation may become an additional source of donor or-
gans once xenograft rejection is resolved.
Critically ill patients are admitted to intensive care
unit prior to the transplantation. Some may require ag-
gressive pharmacologic support or even placement of an
intra-aortic balloon pump is necessary29–35 to maintain
adequate cardiac output and tissue perfusion prior to
transplantation. Mechanical devices such as Ventricular
assist devices (VAD) or total artificial hearts (TAH) may
provide a bridge to transplantation36. Patients with me-
chanical devices have improved survival and quality of
life (REMATCH trial). Approximately 70% of patients
are successfully bridged to transplantation37.
Clinical outcome of heart transplantation has dra-
matically improved with potent immunosuppressive reg-
imen resulting in lesser degree of rejection and improved
survival. The success of cardiac transplantation should
not be measured only by the survival of the patients, but
also by their quality of life.
Conclusion
The number of cardiac transplantations per year is
expected to rise until it reaches the number of available
donors. With advancement in cardioplegic solutions, op-
erative technique and immunosuppressive protocol we
have observed a dramatic drop in the early operative
mortality in the studied period. We have reached the
point of learning curve where we cannot expect further
dramatic decrease in mortality. Additional survival bene-
fit may be seen after introduction of ventricular assisting
devices as a mean of therapy at our institution. Develop-
ment of a ventricular assisting device program will not
eradicate the need for heart transplantations but has a
well-established potential to postpone heart transplanta-
tion. The cut off time for heart ischemia for a trans-
planted heart is 4–6 hours; therefore we are emphasizing
the importance of logistic support (hospital network,
staff education, efficient transportation) to assure ade-
quate graft preservation. Heart transplantation can be
safely performed at our institution with acceptable mor-
tality.
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OSAMNAEST GODINA ISKUSTVA U TRANSPLANTACIJI SRCA – ISKUSTVA JEDNOG CENTRA
S A @ E T A K
Najbolji rezultati u lije~enju sr~anog zatajenja posti`u se transplantacijom srca. Transplantacijski program na Kli-
ni~kom Bolni~kom Centru Rebro Zagreb zapo~eo je 1988. Prema na{im spoznajama ovo je prva retrospektivna studija o
transplantaciji srca u Hrvatskoj koja analizira pre`ivljenje nakon transplantacije srca. Izme|u 1988. i 2006. izvedena je
81 transplantacija srca na KBC Zagreb. Na{a studija se fokusirala na posljednjih 10 godina nakon formiranja Klinike za
kardijalnu kirurgiju kao zasebnog odjela. Trinaest razli~itih bolnica u Hrvatskoj sa~injava mre`u za donaciju organa.
Prosje~na dob primaoca bila je 48±11.8 godina (raspon 14–72), a prosje~na dob donora bila je 34±10.7 godina (raspon
14–56). @ene su ~e{}e bile donori srca (34%), nego primaoci (18%).Tijekom prvih deset godina od 1988–1998 prosje~no je
bilo tri transplantacije srca godi{nje. U razdoblju od 1998–2006 prosje~an broj transplantacija srca porastao je na {est
transplantacija godi{nje. Prosje~an 30 dnevni mortalitet za posljednjih devet godina iznosi 27%. Mortalitet je pao s 30%
i 40% u 1998 i 1999 godini na 0% u posljednje dvije godine. Prosje~na dob umrlih bolesnika iznosila je 50±6.5 godina
(raspon 44–62) i nije se statisti~ki razlikovala od dobi pre`ivjelih bolesnika. Mre`a bolnica donatora pove}ala se na
~etrnaest bolnica diljem zemlje. Transplantacijski programi su limitirani brojem dostupnih donora. Stoga je za for-
miranje dobrog transplantacijskog programa klju~no oformiti u~inkovitu donorsku mre`u. Broj transplantacija o~e-
kivano raste dok ne dosegne broj dostupnih donora. Napredak u operacijskoj tehnici i poslijeoperacijskom tretmanu –
imunosupresivnoj terapiji rezultirao je zamjetnim padom mortaliteta u ranom poslijeoperacijskom razdoblju.
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